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O B J E C T I V E S The goal of this study was to characterize the extent and composition of coronary
atherosclerosis in patients with diabetes mellitus or the metabolic syndrome (Met Syn) presenting with
acute coronary syndromes (ACS).
B A C KG ROUND Diabetes and Met Syn patients have increased rates of major adverse cardiac events
(MACE), yet a systematic description of nonculprit lesions for these high-risk groups is incomplete.
METHOD S In the PROSPECT (Providing Regional Observations to Study Predictors of Events in the
Coronary Tree) study, ACS patients underwent 3-vessel quantitative coronary angiography, grayscale,
and radiofrequency intravascular ultrasound after successful percutaneous coronary intervention (PCI).
Subsequent MACE (cardiac death or arrest, myocardial infarction, or rehospitalization for unstable or
progressive angina) were adjudicated to the originally treated culprit versus untreated nonculprit lesions
in 3 patient groups: 1) diabetes; 2) Met Syn; and 3) neither. Median length of follow-up was 3.4 years.
R E S U L T S Of 673 patients, 119 (17.7%) had diabetes and 239 (35.5%) hadMet Syn. The cumulative 3-year
MACE rate was 29.4% in patients with diabetes, 21.3%with Met Syn, and 17.4%with neither (p 0.03). MACE
adjudicated to untreated nonculprit lesions occurred in 18.7%, 11.7%, and 9.7% of patients, respectively
(p 0.06). Nonculprit lesions in diabetes and Met Syn patients were longer and had greater plaque burden,
smaller lumen areas, with greater necrotic core and calcium content. Diabetes and Met Syn patients with future
MACE had greater necrotic core and calciﬁcation compared with the normal cardiometabolic group.
CONC L U S I O N S In this PCI ACS population, patients with diabetes and Met Syn had higher 3-year
MACE rates. Lesion length, plaque burden, necrotic core, and calcium content were signiﬁcantly greater
among nonculprit lesions of patients with diabetes and Met Syn, but only necrotic core and calcium were
signiﬁcantly greater in the nonculprit lesions of patients with a future MACE in this exploratory
analysis. (J Am Coll Cardiol Img 2012;5:S42–52) © 2012 by the American College of Cardiology Foundation
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S43iabetes mellitus and metabolic syndrome
(Met Syn) are global concerns (1). Nearly
26 million adults in the United States have
diabetes, and 79 million have Met Syn (2).
By 2050, as many as 1 in 3 individuals in the United
States will have diabetes (3). Cardiovascular mor-
tality (4–6) is higher in diabetes and Met Syn
patients, and 24% to 30% of U.S. patients admitted
See page S73
for acute coronary syndromes (ACS) have diabetes
(7,8), a major predictor of mortality (9–13). Retro-
spective studies have demonstrated that patients
with diabetes have more extensive coronary artery
disease (14,15), and atherosclerotic plaque mor-
phology in diabetes patients may be predisposed to
rupture and thrombosis (16).
The PROSPECT (Providing Regional Observa-
tions to Study Predictors of Events in the Coronary
Tree) study, a prospective natural history study of
atherosclerosis, used multimodality coronary imag-
ing in patients at high risk for future cardiac events
following intervention for ACS (17). This report from
the PROSPECT study describes the angiographic,
grayscale, and radiofrequency (RF)-intravascular ultra-
ound (IVUS) characteristics of nonculprit lesions
ccording to patients’ cardiometabolic profiles.
M E T H O D S
Patients. The PROSPECT study was conducted at
7 centers in the United States and Europe. The
rotocol (17,18) and main results have been de-
cribed (17,19–24). Briefly, ACS patients were
nrolled after successful and uncomplicated percu-
aneous coronary intervention (PCI) of all coronary
esions responsible for the index event and remain-
ng angiographically significant stenoses. Angiogra-
hy and grayscale and RF-IVUS of the left main
nd proximal 6 to 8 cm of each major epicardial
oronary artery was performed. Baseline angio-
compensation for Dr. Marso’s research activities, including research grants an
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Quantitative and qualitative coronary angiography.
Angiographic quantitative and qualitative coronary
angiography (QCA) measures of the entire length
of the coronary tree included each epicardial vessel
and side branch 1.5 mm in diameter using meth-
odology modified from Medis CMS software ver-
sion 7.0 (Leiden, the Netherlands). QCA measures
including reference diameter, minimal lumen diam-
eter, and diameter stenosis (percentage of cross-
sectional diameter lost to stenosis) were obtained
every 1.5 mm along the distance of the
coronary artery. Nonculprit lesions were
defined according to QCA or IVUS crite-
ria. Culprit and nonculprit lesions were
defined as 30% visual diameter stenosis
on angiography, with their locations re-
corded in relation to the corresponding
coronary artery ostium and daughter side
branches.
Grayscale and RF-IVUS analyses. Grayscale
nd RF-IVUS analyses were performed
sing: 1) QCU-CMS (Medis) for con-
ouring; 2) pcVH 2.1 (Volcano Corpora-
ion, Rancho Cordova, California) for
ontouring and data output; and 3) pro-
rietary software (qVH, the Cardiovascu-
ar Research Foundation) for segmental
ualitative and quantitative output (27,28).
xternal elastic membrane (EEM) and
umen borders were contoured for each
rame with a median interslice distance of
.40 mm. Quantitative IVUS measure-
ents included EEM cross-sectional area
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S44luminal area (MLA). A nonculprit IVUS lesion was
defined as3 consecutive IVUS frames with40%
plaque burden. RF-IVUS plaque components were
color-coded as fibrous (green), fibrofatty (light-
green), dense calcium (white), and necrotic core
(red) (29,30) and reported as CSA and percentages
of total plaque area. Each RF-IVUS lesion was
further classified by phenotype. A fibroatheroma
was defined by 10% confluent necrotic core. If
30° of necrotic core abutted the lumen in 3
consecutive frames, the fibroatheroma was classified
as thin-cap fibroatheroma (TCFA); otherwise, it
was categorized as thick-cap fibroatheroma. Fi-
brotic plaque was defined as mainly fibrous tissue
with 10% confluent necrotic core, 10% con-
uent dense calcium, and 15% fibrofatty tissue.
ibrocalcific plaque was defined as mainly fibrous
issue with 10% confluent dense calcium, with
10% confluent necrotic core. Pathological inti-
al thickening was defined as 15% fibrofatty
issue, with 10% confluent necrotic core and
10% confluent dense calcium (27). All IVUS
rames and lesions were co-registered to the
ngiographic roadmap using fiduciary side
ranches for alignment.
Deﬁnitions and clinical endpoints. Patients were cat-
gorized as having diabetes, Met Syn (without
iabetes), or no diabetes (without Met Syn). Cate-
ories were mutually exclusive. Diabetes was iden-
ified by self-report and defined as treatment with
xercise and/or diet, oral hypoglycemic agents, or
nsulin. Met Syn was defined by National Choles-
erol Education Program Adult Treatment Panel
ATP) III criteria (31). The primary endpoint was
he incidence of major adverse cardiovascular events
MACE), consisting of cardiac death or arrest,
yocardial infarction (MI), or rehospitalization for
nstable or progressive angina. Endpoints were
djudicated by a committee using original source
ocuments and without knowledge of other patient
ata. On the basis of follow-up angiography, recur-
ent MACE were adjudicated as occurring at ini-
ially treated (culprit) or previously untreated (non-
ulprit) lesions. If follow-up angiography was not
erformed, the event location was classified as
ndeterminate. On the basis of principal results
17), a high-risk lesion was defined as having 2 or
ore of the following: plaque burden 70%, min-
mum lumen area 4.0 mm2, or TCFA.
Statistical analysis. Baseline demographics, imaging
characteristics, and outcomes were compared by
cardiometabolic status. Categorical variables were
summarized using frequencies and percentages and gcompared using chi-square or Fischer exact tests.
Continuous variables were reported as median (in-
terquartile range) and compared using the nonpara-
metric Wilcoxon rank sum test. Outcomes were
summarized as Kaplan-Meier percentages and
numbers of events, and compared using log-rank
tests. A p value 0.05 was considered statistically
significant. A multivariable Cox progression model
was developed to identify predictors of 3-year non-
culprit lesion MACE. Both diabetes and metabolic
syndrome were forced into this multivariable
model. Other candidate covariates included 1
TCFA, patients with 1 lesion with an MLA 4
mm2, age, sex, use of aspirin in the preceding 7
days, and a family history of premature coronary
artery disease. We performed the Kolmogorov su-
premum test, as implemented in the PROC
PHREG procedure of the SAS package (SAS
Institute, Cary, North Carolina) for each of the Cox
regression models reported in our paper. For every
model, the result of the Kolmogorov-type supre-
mum test was p  0.20 (significance established at
p  0.05). Therefore, the “proportional hazards
assumption” was not violated. All statistical analyses
were performed using SAS version 9.2 (SAS
Institute).
R E S U L T S
Baseline characteristics. Cardiometabolic status was
ssessed in 673 (96.5%) of 697 patients enrolled in
he PROSPECT study; 119 (17.7%) and 239
35.5%) had diabetes and Met Syn, respectively.
aseline characteristics by cardiometabolic status
re presented in Table 1. Patients with diabetes
ere older, more often female, and had a history of
ypertension and hypercholesterolemia. In diabetic
atients, mean hemoglobin A1C was 7.1%, and
17.6% were insulin treated. Met Syn patients were
more often female, had greater weight and waist
circumference, had higher blood pressure, and more
often presented with unstable angina.
Clinical outcomes. Table 2 presents cumulative inci-
ences of culprit, nonculprit, and indeterminate
esion MACE at 3 years. MACE occurred more
requently in diabetes and Met Syn patients. Dia-
etic patients had greater rates of cardiac rehospi-
alization and repeat revascularization (Table 2).
here were no significant differences in culprit
esion MACE; however, nonculprit lesion MACE
as greatest in diabetic and intermediate in Met
yn patients, with the differences driven by the
reater need for repeat cardiac rehospitalization and
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S45revascularization (Table 2). The presence of diabe-
tes remained associated with 3-year nonculprit
MACE following multivariable Cox regression
modeling (hazard ratio: 2.08 [95% confidence in-
terval: 1.03 to 4.18]).
Quantitative coronary angiography assessment of all
nonculprit lesions. There were 302 untreated non-
culprit angiographic lesions (visual diameter steno-
sis 30%) identified in patients with diabetes, 594
in Met Syn patients, and 785 in patients without
either. Median length of analyzed segments was
similar in the 3 groups (430.5 [interquartile range
(IQR): 379.5 to 438.5], 435.0 [IQR: 378.0 to
499.5], and 438.0 [IQR: 387.0 to 498.0] mm,
respectively, p  0.45). There were no significant
differences demonstrated by quantitative coronary
angiography between the study groups. The mean
number of vessels with nonculprit lesions was 1.0
(IQR: 1.0 to 2.0), 1.0 (IQR: 1.0 to 2.0), and 1.0
Table 1. Baseline Characteristics According to Cardiometabolic
Normal Cardiometabo
(n  315)
Age, yrs 58.0 (50.2–66.6)
Male 255 (81.0)
Height, inches 68.1 (66.1–70.4)
Weight, lbs 174.6 (158.7–194
Waist circumference, inches 37.7 (34.3–39.8)
Blood pressure, mm Hg
Systolic 129.0 (112.0–141
Diastolic 75.0 (65.0–80.0)
History of CAD 37 (11.9)
History of cardiac intervention 26 (8.3)
Congestive heart failure 5 (1.6)
Family history of CAD 124 (44.1)
Hypertension 100 (32.1)
Hypercholesterolemia 107 (37.8)
History of tobacco use 156 (50.2)
Clinical presentation
ST-segment elevation MI 104 (33.0)
Non–ST-segment elevation MI 199 (63.2)
Unstable angina 12 (3.8)
Serum creatinine, mg/dl 0.90 (0.80–1.06)
Fasting plasma glucose, mg/dl† 96.0 (90.0–107.0
Fasting insulin, IU/ml‡ 7.6 (5.0–12.5)
Hemoglobin A1C, % 5.6 (5.2–5.9)
Total cholesterol, mg/dl 171 (153.194)
Low-density lipoprotein, mg/dl 105 (85.132)
Triglycerides, mg/dl 101 (89.133)
High-density lipoprotein, mg/dl 40 (37.52)
Values are median (interquartile range) or n (% of group). *Three-way compariso
‡To convert the values for fasting insulin to pmol/l, multiply by 6.945.
CAD  coronary artery disease; MI  myocardial infarction.(IQR: 1.0 to 2.0), respectively (p  0.98), and the bnumber of lesions per patient was 2.0 (IQR: 1.0 to
4.0), 2.0 (IQR: 1.0 to 4.0), and 2.0 (IQR: 1.0 to
4.0), p  0.88. These lesions were mild in severity
nd did not vary between groups (median diameter
tenosis: 37.1% [IQR: 31.6% to 45.2%], 38.2%
IQR: 32.2% to 48.9%], and 37.3% [IQR: 31.8% to
5.5%], respectively, p  0.10).
IVUS analysis of nonculprit lesions. Grayscale and
F-IVUS measures of nonculprit lesions are pre-
ented in Table 3. The median length of IVUS-
nalyzed segments was similar in patients with
iabetes, Met Syn, and neither (166 [IQR: 128 to
10] mm, 173 [IQR: 135 to 220] mm, and 177
IQR: 137 to 214] mm, respectively, p  0.40).
here were approximately 5 lesions per patient in
ach group (p  0.87). Average plaque  media
SA was greatest in diabetes and Met Syn patients,
hereas lesion length, EEM, and lumen CSA were
reatest in Met Syn patients (Table 3). Plaque
us
tatus Metabolic Syndrome
(n  239)
Diabetes Mellitus
(n  119)
56.6 (50.1–65.4) 61.8 (53.8–70.8)
170 (71.1) 85 (71.4)
68.1 (65.4–70.5) 67.0 (65.0–70.0)
200.2 (174.2–224.9) 189.6 (163.0–216.0
42.0 (38.8–45.7) 41.0 (37.0–44.9)
134.0 (120.0–149.0) 133.0 (119.0–150.0
78.0 (70.0–89.0) 70.0 (66.0–85.0)
38 (16.4) 19 (16.0)
33 (13.9) 18 (15.1)
3 (1.3) 4 (3.4)
109 (50.7) 32 (32.7)
145 (60.9) 74 (63.2)
99 (46.3) 68 (60.2)
110 (46.8) 46 (39.3)
64 (26.8) 32 (26.9)
156 (66.5) 86 (72.3)
16 (6.7) 1 (0.8)
0.94 (0.80–1.10) 0.90 (0.80–1.10)
108.0 (91.0–121.0) 126.0 (106.0–166.0
11.2 (7.0–18.9) 12.0 (6.0–22.0)
5.7 (5.3–6.1) 6.7 (6.2–7.7)
173 (154.206) 156 (134.191)
103 (81.123) 89 (65.115)
170 (115.208) 144 (97.203)
37 (32.39) 38 (31.48)
diabetes, metabolic syndrome, diabetes). †To convert the values for glucose to mStat
lic S
p Value*
0.004
0.01
0.25
.0) ) 0.0001
0.0001
.0) ) 0.0004
0.006
0.28
0.05
0.35
0.01
0.0001
0.0003
0.13
0.21
0.20
0.03
0.33
) ) 0.0001
0.0001
0.0001
0.02
0.0006
0.001
0.001
n (no mol/l, multiply by 0.0555.urden at the MLA was greatest in diabetes and
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S46Met Syn patients. Median MLA was smallest in
diabetes and largest in Met Syn patients, whereas
median EEM area was numerically greater in Met
Table 2. Composite and Individual Adverse Event Endpoints by
Normal Cardiometabolic
(n  315)
All lesions
Composite MACE 17.4
Cardiac death, arrest, or MI 4.9
Cardiac death 1.7
Cardiac arrest 0.4
MI 3.5
Rehospitalization 14.7
Due to unstable angina 6.2
Due to increasing angina 12.0
Revascularization (PCI or CABG) 15.5
Due to MI 3.2
Due to unstable angina 5.2
Due to increasing angina 10.7
Stent thrombosis 3.1
Death, all-cause 3.8
Culprit lesions
Composite MACE 12.4
Cardiac death, cardiac arrest, or MI 2.1
Cardiac death 0.0
Cardiac arrest 0.4
MI 2.1
Rehospitalization 11.0
Due to unstable angina 4.5
Due to increasing angina 8.3
Revascularization (PCI or CABG) 10.0
Due to MI 2.1
Due to unstable angina 3.5
Due to increasing angina 6.6
Stent thrombosis 1.7
Death, all-cause 0.0
Nonculprit lesions
Composite MACE 9.7
Cardiac death, cardiac arrest, or MI 1.1
Cardiac death 0.0
Cardiac arrest 0.0
MI 1.1
Rehospitalization 9.0
Due to unstable angina 2.4
Due to increasing angina 7.6
Revascularization (PCI or CABG) 9.7
Due to MI 1.1
Due to unstable angina 2.1
Due to increasing angina 7.6
Stent thrombosis 0.0
Death, all-cause 0.0Syn lesions (Table 3).By RF-IVUS, nonculprit lesions in diabetes and
Met Syn patients had greater necrotic core, calcium,
and fibrous content. There were no significant
diometabolic Status and Lesion Type
tus Metabolic Syndrome
(n  239)
Diabetes Mellitus
(n  119) p Value*
21.3 29.4† 0.03
3.6 8.7 0.14
1.8 2.8 0.75
0.0 1.8 0.06
1.8 6.8‡ 0.07
18.8 25.0† 0.05
9.5 10.9 0.25
15.7 21.1 0.06
16.5 26.1†‡ 0.05
1.8 4.9 0.31
7.6 8.9 0.36
12.1 19.3 0.06
2.7 5.6 0.34
1.8 5.5 0.17
12.9 16.2† 0.59
1.3 4.7 0.14
0.4 0.0 0.41
0.0 1.0 0.36
0.9 4.7‡ 0.07
12.6 12.5† 0.82
5.8 2.0 0.28
10.4 11.5 0.52
11.2 14.4†‡ 0.46
0.9 3.7 0.20
4.4 2.0 0.49
9.1 10.6 0.34
1.8 3.7 0.40
0.4 0.0 0.41
11.7 18.7† 0.06
0.9 1.2 0.99
0.0 0.0 0.99
0.0 0.0 0.99
0.9 1.2‡ 0.99
10.8 17.5† 0.06
3.6 5.9 0.26
7.6 13.6 0.15
9.9 16.7†‡ 0.14
0.9 1.2 0.99
3.2 5.9 0.17
5.8 11.6 0.19
0.0 0.0 0.99
0.0 0.0 0.99
Continued on next pageCar
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S47groups. Diabetic patients, compared with those
with Met Syn or normal cardiometabolism, were
more likely to have 1 nonculprit lesions with 2
igh-risk plaque features (51.3% vs. 46.9% vs.
9.5%, respectively, p  0.03), defined as MLA
4.0 mm2, plaque burden 70%, or TCFA.
Grayscale and RF-IVUS analysis of all nonculprit lesions
in study patients with a future MACE. There were 75
atients with at least 1 MACE adjudicated to 104
onculprit lesions (Table 4). The QCA median
ercent diameter stenosis at baseline for diabetes,
et Syn, and neither was 39.5% (IQR: 31.7% to
2.9%), 47.0% (IQR: 25.1% to 38.4%), and 31.6%
IQR: 18.2% to 47.3%), respectively, and increased to
1.8% (IQR: 59.6% to 77.4%), 62.0% (IQR: 53.9% to
4.0%), and 65.4% (IQR: 55.2% to 76.9%) at the
ime of the follow-up event (each p  0.0001
ompared with baseline). There were no differences
n baseline angiographic reference vessel size, lesion
ength, or minimum lumen diameter of the noncul-
rit MACE-related lesions between study groups
data not shown).
In contrast to all nonculprit lesions, there were no
ifferences in grayscale measures of baseline plaque
urden or lesion dimensions in MACE-related
onculprit lesions between study groups (Table 4).
owever, diabetic patients with MACE-related
onculprit events had significantly greater necrotic
ore and calcium area compared with diabetic
atients without a nonculprit-related event (Fig. 1).
nline Tables 1A and 1B provide grayscale and
F-IVUS comparisons for patients with and with-
Table 2. Continued
Normal Cardiometabolic
(n  315)
Indeterminate lesions
Composite MACE 1.7
Cardiac death, cardiac arrest, or MI 1.7
Cardiac death 1.7
Cardiac arrest 0.0
MI 0.3
Rehospitalization 0.0
Due to unstable angina 0.0
Due to increasing angina 0.0
Revascularization (PCI or CABG) 0.0
Due to MI 0.0
Due to unstable angina 0.0
Due to increasing angina 0.0
Stent thrombosis 1.4
Death, all-cause 3.8
Values are % of group. *Three-way comparison (no diabetes, metabolic syndrom
CABG  coronary artery bypass graft; MACE  major adverse cardiovascularut nonculprit MACE. Although there were mea-urable differences in nonculprit lesions in patients
ith MACE, the differences in composition were
rincipally driven by diabetic patients.
D I S C U S S I O N
This pre-specified substudy from PROSPECT
demonstrates 4 novel findings. First, although the
frequency of culprit lesion MACE was similar
among patients with diabetes, Met Syn, and normal
cardiometabolic status, the rates of nonculprit
lesion–related MACE were nearly twice as high in
patients with diabetes as compared with normogly-
cemic status and intermediate in patients with Met
Syn. These differences were driven by greater rates
of cardiac rehospitalization for unstable angina and
repeat revascularization in patients with impaired
glucose metabolism. Second, plaque area, burden,
and necrotic core content were quantifiably greater
in untreated nonculprit plaques of patients with
either diabetes or Met Syn. Third, diabetic as
compared with nondiabetic patients had a greater
frequency of at least 1 nonculprit lesion containing
2 high-risk plaque features shown to correlate
with future unanticipated MACE. Finally, the
nonculprit lesions of patients with a future MACE
had similar plaque burden, but measurable differ-
ences in composition were present among diabetic
patients. Namely, diabetic nonculprit lesions exhib-
ited significantly greater necrotic core and calcium
content at baseline.
The long-term prognosis of diabetic patients
tus Metabolic Syndrome
(n  239)
Diabetes Mellitus
(n  119) p Value*
2.7 5.7† 0.10
1.4 3.7 0.29
1.4 2.8 0.62
0.0 0.9 0.09
0.0 1.0‡ 0.35
1.4 2.0† 0.09
0.5 2.0 0.05
0.9 0.0 0.17
0.0 0.0 0.99
0.0 0.0 0.99
0.0 0.0 0.99
0.0 0.0 0.99
0.9 1.9 0.74
1.4 5.5 0.09
iabetes). †p  0.05 versus no diabetes. ‡p  0.05 versus metabolic syndrome.
ts; MI  myocardial infarction; PCI  percutaneous coronary intervention.Sta
e, dfollowing PCI and ACS (11,12) has consistently
CSA  cross-sectional are inim
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S48been demonstrated to be poor, with increased rates
of restenosis, stent thrombosis, nonfatal MI, and
late death (32). Coronary angiography has demon-
strated that patients with diabetes have a greater
prevalence of multivessel disease, manifesting as
longer coronary lesions with smaller reference vessel
diameters. In sudden cardiac death patients, Burke
et al. (33) reported greater proximal and distal
plaque burden admixed with confluent necrotic core
of nonobstructive coronary artery lesions in patients
with as opposed to without diabetes (11.6% vs.
9.5%, p  0.04). Additionally, the diabetic cohort
had a numerically greater amount of mixed calcifi-
cation and plaque characterized as fibroatheroma
(8.8  4.3 vs. 6.9  4.7 per patient, p  0.02), but
d RF-IVUS Measures of All Patients and Untreated Nonculprit Le
Normal Cardiometabolic Status
(n  315 Patients and
1,326 Lesions*)
M
(n
10.7 (5.3–21.5)
, mm2 15.22 (11.77–19.22)
A, mm2 7.77 (5.97–10.07)
media CSA, mm2 7.24 (5.54–9.30)
13.97 (10.42–17.87)
iameter, mm 2.49 (2.12–2.89)
rea, mm2 5.98 (4.32–7.97)
273 (18.7)
CSA, mm2 7.61 (5.61–10.36)
55.0 (48.6–62.1)
70% 109 (7.5)
core CSA, mm2 0.37 (0.18–0.73)
SA, mm2 0.15 (0.06–0.33)
SA, mm2 2.18 (1.41–3.19)
CSA, mm2 0.71 (0.34–1.30)
, mm2 0.5 (0.2–0.9)
2 0.1 (0.0–0.4)
2.6 (1.6–3.9)
m2 0.8 (0.3–1.5)
a 788 (59.4)
roma 277 (20.9)
eroma 511 (38.5)
al thickening 490 (37.0)
17 (1.3)
artile range) or n (% of group). *For grayscale IVUS and radiofrequency IVUS, respec
s normal cardiometabolic status. §p  0.05 versus metabolic syndrome. p  0.0
a; EEM  external elastic membrane; IVUS  intravascular ultrasound; MLA  mnot a greater number of TCFAs. Such retrospec-tive observations, along with a prior atherectomy
study (34), suggest greater inflammation and
macrophage content in the coronary plaque of
diabetic patients.
RF-IVUS findings have demonstrated that target
vessels in patients with diabetes and stable angina
(Canadian Cardiovascular Society class I or II) are
more likely to have confluent necrotic core (11%
[IQR: 7.2% to 15.2%] vs. 7.6% [IQR: 5.6% to
13.2%], p  0.03) (36). The presence of at least 1
RF-IVUS–identified TCFA lesion in this popula-
tion was nearly twice as common in patients with
than without diabetes (75% vs. 41%, p  0.001),
and 53% of the diabetic cohort had both an RF-
IVUS TCFA and fibroatheroma compared with
s
bolic Syndrome
239 Patients and
76 Lesions*)
Diabetes Mellitus
(n  119 Patients and
501 Lesions*) p Value†
.9 (6.1–22.20)‡ 12.0 (6.3–21.8) 0.04
0 (12.28–20.52)‡ 15.61 (11.40–19.72)§ 0.004
4 (6.21–10.66)‡ 7.62 (5.85–9.95)§ 0.01
4 (5.86–10.02)‡ 7.60 (5.48–9.94)‡ 0.0003
0 (10.85–19.15)‡ 14.56 (10.41–17.97) 0.06
9 (2.12–2.95) 2.41 (2.09–2.84)§ 0.07
2 (4.32–8.42) 5.64 (4.15–7.84)§ 0.08
2 (18.9) 123 (22.4) 0.15
6 (5.95–10.93)§ 8.19 (5.88–10.78)‡ 0.004
.8 (49.5–63.5)‡ 56.8 (50.2–64.6)‡§ 0.0006
9 (9.7)‡ 66 (12.0)‡ 0.004
2 (0.22–0.77) 0.42 (0.22–0.81) 0.01
8 (0.07–0.37)‡ 0.18 (0.07–0.40)‡ 0.008
5 (1.60–3.69)‡ 2.46 (1.46–3.58)‡ 0.0001
7 (0.39–1.39)‡ 0.79 (0.41–1.34) 0.07
.5 (0.2–1.1)‡ 0.6 (0.2–1.1)‡ 0.005
.2 (0.0–0.5)‡ 0.2 (0.0–0.5)‡ 0.003
.8 (1.8–4.3)‡ 2.8 (1.7–4.3)‡ 0.0007
.8 (0.3–1.6) 0.8 (0.4–1.5) 0.32
7 (61.2) 298 (59.5) 0.67
9 (23.5) 113 (22.6) 0.33
8 (37.7) 185 (36.9) 0.80
8 (35.7) 179 (35.7) 0.78
8 (0.8) 7 (1.4) 0.49
y. †Three-way comparison (normal cardiometabolic status, metabolic syndrome,
rsus normal cardiometabolic status.
um luminal area; RF  radiofrequency.Table 3. Grayscale an sion
eta

9
Grayscale IVUS
Overall
Lesion length, mm 11
Average EEM CSA 16.0
Average lumen CS 8.0
Average plaque  7.7
MLA site
EEM CSA (mm2) 14.4
Minimum lumen d 2.4
Minimum lumen a 5.9
MLA 4 mm2 21
Plaque and media 7.9
Plaque burden 55
Plaque burden  10
Radiofrequency IVUS
Composition
Average necrotic 0.4
Average calcium C 0.1
Average ﬁbrous C 2.4
Average ﬁbrofatty 0.7
MLA site
Necrotic core CSA 0
Calcium CSA, mm 0
Fibrous CSA, mm2 2
Fibrofatty CSA, m 0
Lesion phenotypes
Any ﬁbroatherom 59
Thin-cap ﬁbroathe 22
Thick-cap ﬁbroath 36
Pathological intim 34
Fibrocalciﬁc
Values are median (interqu tivel
diabetes). ‡p  0.05 versu 6 ve17% of the nondiabetic group (p  0.0004). In a
g
(
1
t
0
(
p
I
k
f
S
d
y
e
I
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0
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fi
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a
A
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 3 , S U P P L S , 2 0 1 2
M A R C H 2 0 1 2 : S 4 2 – 5 2
Marso et al.
Cardiometabolic Plaque Composition
S49study of 775 patients from the Global IVUS-VH
Registry, patients with diabetes (n  191) had a
reater proportion of IVUS–virtual histology
VH)–identified TCFA in the most diseased
0-mm segment (21.6% vs. 13.6%), a difference
hat was statistically significant in univariate (p 
.01) but attenuated after multivariable adjustment
p  0.08) (36). A separate registry of diabetic PCI
atients (76% with stable angina) undergoing RF-
VUS suggests that duration of diabetes may be a
ey multivariable factor associated with increased
requency of TCFA in the worst 10-mm segment.
pecifically, patients with a reported history of
iabetes 10 years in duration compared with 10
ears had greater plaque burden in the most dis-
Table 4. Grayscale and RF-IVUS Measures of All Nonculprit Lesi
Normal Cardiometabo
(n  28 Patien
and 115 Lesion
Grayscale
Overall
Lesion length, mm 12.0 (5.9–24.8)
Average EEM CSA, mm2 14.34 (11.13–19.0
Average lumen CSA, mm2 7.30 (5.59–9.04)
Average plaque  media CSA, mm2 6.99 (5.57–9.16)
Site of minimal lumen area
EEM CSA (mm2) 13.05 (9.54–16.44
Minimum lumen diameter, mm 2.28 (1.97–2.70)
Minimum lumen area, mm2 5.02 (3.80–7.02)
MLA  4 mm2 41 (28.9)
Plaque and media CSA, mm2 7.52 (5.34–10.27
Plaque burden 58.4 (50.7–65.1)
Plaque burden  70% 18 (12.7)
Radiofrequency IVUS
Composition
Average necrotic core CSA, mm2 0.36 (0.16–0.77)
Average calcium CSA, mm2 0.14 (0.04–0.42)
Average ﬁbrous CSA, mm2 2.25 (1.51–3.31)
Average ﬁbrofatty CSA, mm2 0.58 (0.29–1.39)
MLA site
Necrotic core CSA, mm2 0.43 (0.15–0.98)
Calcium CSA, mm2 0.14 (0.02–0.47)
Fibrous CSA, mm2 2.70 (1.53–4.14)
Fibrofatty CSA, mm2 0.71 (0.29–1.55)
Lesion phenotypes
Any ﬁbroatheroma 71 (61.7)
Thin-cap ﬁbroatheroma 26 (22.6)
Thick-cap ﬁbroatheroma 45 (39.1)
Pathological intimal thickening 40 (34.8)
Fibrocalciﬁc 3 (2.6)
Values are median (interquartile range) or n (% of group). *For grayscale IVUS and
status, metabolic syndrome, diabetes). ‡p  0.05 versus normal cardiometabol
Abbreviations as in Table 3.ased 10-mm segment and a higher proportion ofVUS-VH–defined TCFA (54% [IQR: 11.6% to
7.5%] vs. 10.8% [IQR: 0.0% to 26.1%], p 
.009) (37). TCFA frequency in this study was
nrelated to age, sex, lipid status, ACS presenta-
ion, smoking, congestive heart failure, baseline
emoglobin A1C, and diabetes treatment.
Few studies (35,37,38) have evaluated RF-IVUS
ndings in diabetic patients with ACS. Hong et al.
39) demonstrated greater necrotic core content and
higher frequency of at least 1 TCFA in diabetic
CS patients (60% vs. 42%, p  0.003) and a
higher frequency of multiple culprit lesion TCFAs
(25% vs. 11%, p  0.001), an association that
persisted following multivariable adjustment. Al-
though nonculprit lesions were not systematically
Responsible in Patients With a Future MACE
tatus Metabolic Syndrome
(n  27 Patients
and 96 Lesions*)
Diabetes Mellitus
(n  20 Patients
and 92 Lesions*) p Value†
13.2 (6.7–24.0) 14.0 (7.3–29.8) 0.56
15.76 (11.84–20.38) 16.33 (10.77–20.08) 0.24
7.84 (6.01–10.27) 8.06 (5.85–9.87) 0.27
7.55 (5.78–10.03) 8.15 (5.49–10.30) 0.20
14.09 (10.87–19.34) 14.77 (10.38–17.67) 0.19
2.47 (2.07–2.92) 2.31 (2.06–2.81) 0.28
5.81 (4.21–8.24) 5.05 (3.91–7.46) 0.35
28 (22.6) 26 (27.7) 0.48
7.78 (6.12–11.26)† 9.07 (6.16–11.03) 0.12
56.8 (50.6–65.0) 61.7 (51.8–68.7) 0.12
16 (12.9) 19 (20.2) 0.22
0.46 (0.24–0.76) 0.64 (0.29–1.06)‡§ 0.01
0.18 (0.07–0.40) 0.29 (0.13–0.54)‡§ 0.004
2.59 (1.57–3.76) 2.71 (1.45–3.79) 0.49
0.79 (0.42–1.42) 0.72 (0.29–1.31) 0.39
0.45 (0.20–1.04) 0.76 (0.32–1.35)‡§ 0.01
0.19 (0.03–0.55) 0.31 (0.10–0.80)‡§ 0.003
2.89 (1.75–4.49) 3.02 (1.63–4.68) 0.54
0.74 (0.36–1.95) 0.68 (0.32–1.64) 0.31
61 (63.5) 62 (67.4) 0.70
23 (24.0) 28 (30.4) 0.40
38 (39.6) 34 (37.0) 0.92
31 (32.3) 28 (30.4) 0.80
2 (2.1) 1 (1.1) 0.73
ofrequency IVUS, respectively. †Three-way comparison (normal cardiometabolic
tus. §p  0.05 versus metabolic syndrome.ons
lic S
ts
s*)
1)
)
)
radi
ic staevaluated, these investigators noted that proximal
l
o
d
s
a
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c
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e
w
w
A
denotes nonculprit les
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S50and distal reference sites within 10 mm of the
culprit lesion in diabetic patients contained greater
necrotic core and dense calcium. Patients with
diabetes also had more overall plaque ruptures,
including multiple ruptures, and thrombus forma-
tion per grayscale IVUS findings.
In contrast to prior studies, the PROSPECT
study was a prospectively designed study and in-
cluded systematic assessment of all major epicardial
vessels in patients presenting with ACS. Ascertain-
ment of both diabetes and Met Syn status was
planned (including measurement of waist circum-
ference and fasting glucose and insulin levels), and
the present analysis was pre-specified. Nonculprit
lesions were prospectively identified using both
quantitative coronary angiography and IVUS. The
present findings indicate an association between
plaque burden, vessel and lumen dimensions, and
compositional differences in nonculprit lesions ac-
cording to cardiometabolic state.
Patients with diabetes and Met Syn had greater
grayscale IVUS measures of plaque burden, vessel
expansion, and smaller lumen areas than patients
with normal cardiometabolic status. At the MLA
site, these findings were more pronounced in pa-
tients with diabetes, although patients with Met
Syn had greater measures of vessel expansion (larger
EEM) and extent of plaque throughout the coro-
nary tree. Patients with impaired cardiometabolism
also had greater necrotic core and calcium content.
Tissue Types of Lesions in Diabetic Patients With Versus
main tissue types in diabetic lesions with (n  92) versus without
se cardiovascular events (MACE) during follow-up. NCL MACE
ion–related major adverse cardiac events.The number of high-risk nonculprit lesions wasgreatest in patients with diabetes, intermediate in
Met Syn, and least in patients having neither.
Study limitations. Duration of diabetes has been
inked with poor outcomes and increased frequency
f TCFA; however, patient-reported duration of
iabetes was not collected in the PROSPECT
tudy. The association between disease duration
nd high-risk vulnerable plaque features, therefore,
ould not be examined. Although PROSPECT
onstituted a relatively high-risk ACS population
almost all troponin positive, 30% with ST-segment
levation MI), in all likelihood, those with diabetes
ere highly selected. For example, glucose levels
ere relatively well controlled (mean hemoglobin
1c: 7.1%). Additionally, elderly and renally im-
paired patients are often underrepresented in pro-
spective clinical studies. Therefore, the differences
we report in both grayscale and compositional
content of these nonculprit plaques may be under-
stated. Finally, it is plausible that calcified TCFAs
are an important determinant of risk (35,40) but
were not further characterized in this report.
The findings from this paper ought to be consid-
ered exploratory and unlikely to practically impact
routine medical decision making, but rather are di-
rectly applicable to future research related to diabetes,
Met Syn, and vulnerable plaque development.
It should also be recognized that IVUS-VH, sim-
ilar to other imaging platforms, is inherently limited
when used to study vulnerable plaque. The sensitivity
and specificity of IVUS-VH in detecting plaque com-
position has varied in several reports (30,41,42). The
axial resolution of IVUS-VH is also several-fold
greater than the resolution required to precisely dis-
criminate the presence and thickness of thin cap
overlying fibroatheroma. Therefore, the ability to fur-
ther risk stratify TCFA using IVUS-VH is limited.
Lastly, the generalizability of these findings in clinical
practice is unknown. It is widely recognized that small
alterations in border detection impact compositional
analyses (42).
C O N C L U S I O N S
In this PCI ACS population, patients with diabetes
and Met Syn had a higher 3-year MACE rate.
Measures of lesion length, plaque burden, necrotic
core, and calcium were significantly greater for pa-
tients with either diabetes or Met Syn in all NCLs.
However, only necrotic core and calcium were signif-
icantly greater in the nonculprit lesions of diabetic
patients with a future MACE. These exploratory dataFigure 1. The 4 Main
Without MACE
Average area of the 4
(n  409) major adversuggest that there are quantifiable compositional dif-
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S51ferences between diabetic and nondiabetic plaques
that may explain their greater propensity for future
adverse cardiovascular events.
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